Cutler Group LP Capricor Therapeutics, Inc. Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$3.42 - $7.85 $2,394 - $5,495	-700 Reduced 41.18%	1,000 $3,000
Q1 2023 May 01, 2023	SELL	$3.78 - $5.03 $4,993 - $6,644	-1,321 Reduced 43.73%	1,700 $7,000
Q4 2022 Feb 07, 2023	SELL	$3.36 - $6.55 $2,688 - $5,240	-800 Reduced 20.94%	3,021 $11,000
Q2 2022 Aug 04, 2022	SELL	$2.89 - $4.51 $5,780 - $9,020	-2,000 Reduced 34.36%	3,821 $13,000
Q1 2022 Apr 14, 2022	SELL	$2.83 - $5.68 $21,508 - $43,168	-7,600 Reduced 56.63%	5,821 $19,000
Q4 2021 Jan 18, 2022	SELL	$2.89 - $4.16 $2,661 - $3,831	-921 Reduced 6.42%	13,421 $39,000
Q3 2021 Oct 26, 2021	BUY	$3.8 - $5.23 $23,012 - $31,672	6,056 Added 73.09%	14,342 $57,000
Q2 2021 Jul 19, 2021	BUY	$3.16 - $5.72 $20,811 - $37,671	6,586 Added 387.41%	8,286 $42,000
Q4 2020 Jan 21, 2021	SELL	$3.43 - $5.23 $6,952 - $10,601	-2,027 Reduced 54.39%	1,700 $5,000
Q3 2020 Oct 27, 2020	BUY	$4.08 - $9.81 $15,206 - $36,561	3,727 New	3,727 $19,000

8.13M

1.78M

1.4M

Ticker CAPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,346,200
Market Cap $318M
Description
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.